A randomised, double-blind, placebo-controlled trial to assess the effect of phosphate reduction with lanthanum carbonate on arterial compliance and vascular calcification in patients with chronic kidney disease stages 3-4

一项随机、双盲、安慰剂对照试验，旨在评估碳酸镧还原磷酸盐对 3-4 期慢性肾病患者动脉顺应性和血管钙化的影响

• 批准号: nhmrc : 1044302
• 负责人: A/Pr Carmel Hawley
• 金额: $ 111.27万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/randomised-double-blind-3-4/111648
• 关键词: randomised; double; blind; placebo; controlled

Chronic kidney disease (CKD) is a significant health problem and is associated with an increased risk of cardiovascular (CV) disease. Vascular calcification and arterial stiffness (stiffening of the blood vessels and arteries) are very common in people with CKD, and are linked to increased death from CV events. This study aims to examine the ways in which treatment with a phosphate binder, Lanthanum Carbonate, may reduce vascular calcification and arterial stiffness to decrease CV events.

慢性肾脏疾病(CKD)是一个严重的健康问题，并与心血管疾病(CV)风险增加有关。血管钙化和动脉僵硬(血管和动脉硬化)在CKD患者中非常常见，并与心血管事件死亡增加有关。这项研究旨在研究使用磷酸粘合剂碳酸镧治疗可以减少血管钙化和动脉僵硬以减少心血管事件的方法。